Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer

  • Authors:
    • Xiaorong Qi
    • Xiangrong Song
    • Ping Liu
    • Tao Yi
    • Shuangzhi Li
    • Chuan Xie
    • Yu Zheng
    • Yu Bai
    • Chuntang Sun
    • Yuquan Wei
    • Xia Zhao
  • View Affiliations

  • Published online on: June 6, 2011     https://doi.org/10.3892/or.2011.1337
  • Pages: 703-710
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human PNAS-4 (hPNAS-4), as a pro-apoptotic gene, can inhibit tumor growth when overexpressed in some malignant cells. Poly (lactic-co-glycolic acid) (PLGA) was used as a gene transfer vector due to the advantage of sustained release, nontoxicity and biodegradability. In this study, we aimed to investigate the effect of PLGA nanoparticles encapsulating hPNAS-4 combined with cisplatin (DDP) on ovarian carcinoma. Expression of hPNAS-4 was determined by RT-PCR. Mice bearing intraperitoneal ovarian carcinomas were treated with PBS, pVAX-PLGA nanoparticles (P-P), pVAX-hPNAS-4-PLGA nanoparticles (PhP-P), DDP and PhP-P plus DDP, respectively. Intraperitoneal tumors were weighed to assess the antitumor efficacy. The percentage of proliferative cells and apoptotic cells was evaluated by Ki-67 staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling. The anti-angiogenic effects were detected by CD31 staining and the alginate-encapsulate assay. Overexpression of hPNAS-4 was detected by RT-PCR in the PhP-P and PhP-P plus DDP groups. PhP-P exerted significant antitumor activity through induction of apoptosis, inhibition of cell proliferation and suppression of angiogenesis, compared with treatment with P-P or PBS alone. The combination of PhP-P with DDP showed enhanced antitumor activity compared with therapy of PhP-P or DDP alone. PLGA encapsulating hPNAS-4 combined with DDP may have promising applications in the therapy of ovarian cancer.

Related Articles

Journal Cover

September 2011
Volume 26 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Qi X, Song X, Liu P, Yi T, Li S, Xie C, Zheng Y, Bai Y, Sun C, Wei Y, Wei Y, et al: Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer. Oncol Rep 26: 703-710, 2011.
APA
Qi, X., Song, X., Liu, P., Yi, T., Li, S., Xie, C. ... Zhao, X. (2011). Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer. Oncology Reports, 26, 703-710. https://doi.org/10.3892/or.2011.1337
MLA
Qi, X., Song, X., Liu, P., Yi, T., Li, S., Xie, C., Zheng, Y., Bai, Y., Sun, C., Wei, Y., Zhao, X."Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer". Oncology Reports 26.3 (2011): 703-710.
Chicago
Qi, X., Song, X., Liu, P., Yi, T., Li, S., Xie, C., Zheng, Y., Bai, Y., Sun, C., Wei, Y., Zhao, X."Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer". Oncology Reports 26, no. 3 (2011): 703-710. https://doi.org/10.3892/or.2011.1337